VITROS Immunodiagnostic Products hs Troponin I

NCT ID: NCT03581578

Last Updated: 2020-09-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1630 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-07

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical study is to collect data to substantiate the use of the VITROS hs Troponin I test as an aid in the diagnosis of myocardial infarction (MI). The test is further indicated for risk stratification of mortality, myocardial infarction or coronary revascularization in patients with acute coronary syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective clinical sample collection and cardiac troponin I testing will be conducted in individuals presenting to the Emergency Department (ED) with signs and/or symptoms suggestive of acute coronary syndrome (ACS) at geographically dispersed sites in the US. Individuals who meet the inclusion/exclusion criteria, including having signed an informed consent form will be included in the study.

Clinical and laboratory data will be collected to demonstrate product performance compared to an adjudicated clinical diagnosis.

Sample collection and testing of clinical samples with the VITROS hs Troponin I test will be performed under two separate protocols.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome (ACS) Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject must be ≥22 years of age at the time of consent.
2. Subject presenting with symptoms suggestive of acute coronary syndrome including chest pain, or chest pain equivalent.
3. Must have an Electrocardiogram (ECG) ordered as part of the subject's standard of care.
4. Subject willing and able to provide informed consent.

Exclusion Criteria

1. Subject is unable to comply with the study requirements.
2. Any samples which were not obtained under IRB approved protocol.
Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ortho-Clinical Diagnostics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fred Apple, PhD

Role: PRINCIPAL_INVESTIGATOR

Hennepin Healthcare Research Institute

Richard Nowak, MD

Role: PRINCIPAL_INVESTIGATOR

Henry Ford Health System

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Drug Research and Analysis Corp

Montgomery, Alabama, United States

Site Status

Chandler Regional Medical Center

Chandler, Arizona, United States

Site Status

Yale New Haven Hospital

New Haven, Connecticut, United States

Site Status

University of Kansas Medical Center

Kansas City, Kansas, United States

Site Status

University of Maryland

Baltimore, Maryland, United States

Site Status

Mass General Hospital

Boston, Massachusetts, United States

Site Status

Wayne State University/Detroit Receiving Hospital

Detroit, Michigan, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

Beaumont

Royal Oak, Michigan, United States

Site Status

Hennepin County Medical Center/Minneapolis Medical Research Foundation

Minneapolis, Minnesota, United States

Site Status

Cooper University Hospital

Camden, New Jersey, United States

Site Status

Stony Brook University Hospital

Stony Brook, New York, United States

Site Status

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

Oregon Health Science University Hospital

Portland, Oregon, United States

Site Status

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

UT Southwestern Medical Center

Dallas, Texas, United States

Site Status

Texas Tech University Health Sciences Center El Paso

El Paso, Texas, United States

Site Status

Ben Taub General Hospital / Baylor College of Medicine/Harris Health System

Houston, Texas, United States

Site Status

INOVA Alexandria Hospital

Alexandria, Virginia, United States

Site Status

Virginia Commonwealth University Medical Center

Richmond, Virginia, United States

Site Status

Charleston Area Medical Center

Charleston, West Virginia, United States

Site Status

Medical College of Wisconsin and Froedtert Hospital

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

16-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.